# Adlai Nortye Group Ltd.: overview ANL · Nasdaq · CIK 1944552 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/anl.md) · [Financials](/companies/anl/financials.md) · [Filings](/companies/anl/filings.md) · [Insiders](/companies/anl/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | [45.7](/filings/0001213900-25-014428.md) | not reported | [5.0](/filings/0001213900-25-041663.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | [(18.9%)](/filings/0001213900-25-014428.md) | not reported | [(1451.0%)](/filings/0001213900-25-041663.md) | not reported | | Net margin | % | [(124.0%)](/filings/0001213900-25-014428.md) | not reported | [(2184.6%)](/filings/0001213900-25-041663.md) | not reported | | Diluted EPS | $ per share | [(2.23)](/filings/0001213900-25-014428.md) | [(2.31)](/filings/0001213900-25-041663.md) | [(2.52)](/filings/0001213900-25-041663.md) | [(0.54)](/filings/0001213900-25-041663.md) | | Free cash flow | $m | [(4.1)](/filings/0001213900-25-014428.md) | [(44.5)](/filings/0001213900-25-041663.md) | [(56.9)](/filings/0001213900-25-041663.md) | [(52.0)](/filings/0001213900-25-041663.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/anl/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Cormorant Asset Management, LP](/funds/1583977.md) | 2026-06-30 | $45.7m | 3,978,229 | | Added +1,080,372 | | [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $36.9m | 3,212,731 | | Unchanged | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $35.2m | 3,061,668 | | Added +2,183,822 | | [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $24.6m | 2,140,664 | | New +2,140,664 | | [MPM BIOIMPACT LLC](/funds/1687078.md) | 2026-06-30 | $22.3m | 1,936,291 | | New +1,936,291 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $20.6m | 1,793,190 | | New +1,793,190 | | [Casdin Capital, LLC](/funds/1534261.md) | 2026-06-30 | $14.4m | 1,250,000 | | Added +711,539 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $11.7m | 1,017,805 | | Added +899,896 | | [Octagon Capital Advisors LP](/funds/1839435.md) | 2026-06-30 | $10.7m | 934,716 | | New +934,716 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $9.3m | 807,832 | | Added +126,057 | ## Recent filings [All 114 filings](/companies/anl/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-28 | 06:04 ET | [6-K](/filings/0001213900-26-113051.md) | Report of a foreign private issuer, period 2026-10-28 | 0001213900-26-113051 | | 2026-10-15 | 07:00 ET | [6-K](/filings/0001213900-26-109576.md) | Report of a foreign private issuer, period 2026-10-15 | 0001213900-26-109576 | | 2026-09-30 | 08:30 ET | [6-K](/filings/0001213900-26-104908.md) | Report of a foreign private issuer, period 2026-09-30 | 0001213900-26-104908 | | 2026-09-30 | 06:04 ET | [6-K](/filings/0001213900-26-104846.md) | Report of a foreign private issuer, period 2026-09-30 | 0001213900-26-104846 | | 2026-09-08 | 08:00 ET | [6-K](/filings/0001213900-26-097850.md) | Report of a foreign private issuer, period 2026-09-08 | 0001213900-26-097850 | | 2026-08-26 | 09:07 ET | [6-K](/filings/0001213900-26-093761.md) | Report of a foreign private issuer, period 2026-08-26 | 0001213900-26-093761 | | 2026-08-19 | 08:30 ET | [6-K](/filings/0001213900-26-091426.md) | Report of a foreign private issuer, period 2026-08-19 | 0001213900-26-091426 | | 2026-08-14 | 07:22 ET | [6-K](/filings/0001213900-26-089447.md) | Report of a foreign private issuer, period 2026-08-14 | 0001213900-26-089447 | | 2026-08-03 | 08:00 ET | [6-K](/filings/0001213900-26-084256.md) | Report of a foreign private issuer, period 2026-08-03 | 0001213900-26-084256 | | 2026-07-17 | 21:06 ET | [6-K](/filings/0001213900-26-078874.md) | Report of a foreign private issuer, period 2026-07-16 | 0001213900-26-078874 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-042520.md), filed Apr 10, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1944552 - Tickers: ANL - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: U0 - Filer category: Non-accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 06:06 ET. No prices; not investment advice.